^
Association details:
| Biomarker: | FLT3-ITD mutation |
|---|---|
| Cancer: | Acute Myelogenous Leukemia |
| Drug: | Vanflyta (quizartinib) (FLT3 inhibitor) + eragidomide (CC-90009) (GSPT1 degrader, Ubiquitin pathway modulator) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
Synergistic Combination Activity of the Novel GSPT1 Degrader CC-90009 in Acute Myeloid Leukemia Models
Published date:
11/04/2021
Excerpt:
We characterized FLT3 inhibitor/CC-90009 and BCL2 inhibitor/AZA/CC-90009 combinations in a FLT3-ITD PDX murine model, PDX1. The FLT3 inhibitor quizartinib significantly prolonged survival when combined with CC‑90009 compared with either agent alone (P < 0.001).
DOI:
10.1182/blood-2021-147160
